RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy

Hua, Hongchen; Zhang, Xuemei; Mu, Hongjie; Meng, Qingqing; Jiang, Ying; Wang, Yiyun; Lu, Xiaoyan; Wang, Aiping; Li, Sha; Zhang, Yaping; Wan, Zhaohui; Sun, Kaoxiang

doi:10.1016/j.ijpharm.2018.03.028

Cited by 57 publications

(34 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, NP-mediated drug delivery is emerging as an effective and non-invasive system to treat brain diseases. Nanotechnology-based BBB crossing has been successfully demonstrated in preclinical animal studies of different neurological disorders such as Alzheimer's disease (260), brain cancer (261), and even stroke (262).…”

Section: Discussionmentioning

confidence: 99%

Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery

et al. 2020

View full text Add to dashboard Cite

The blood–brain barrier (BBB) is a dynamic interface responsible for maintaining the central nervous system homeostasis. Its unique characteristics allow protecting the brain from unwanted compounds, but its impairment is involved in a vast number of pathological conditions. Disruption of the BBB and increase in its permeability are key in the development of several neurological diseases and have been extensively studied in stroke. Ischemic stroke is the most prevalent type of stroke and is characterized by a myriad of pathological events triggered by an arterial occlusion that can eventually lead to fatal outcomes such as hemorrhagic transformation (HT). BBB permeability seems to follow a multiphasic pattern throughout the different stroke stages that have been associated with distinct biological substrates. In the hyperacute stage, sudden hypoxia damages the BBB, leading to cytotoxic edema and increased permeability; in the acute stage, the neuroinflammatory response aggravates the BBB injury, leading to higher permeability and a consequent risk of HT that can be motivated by reperfusion therapy; in the subacute stage (1–3 weeks), repair mechanisms take place, especially neoangiogenesis. Immature vessels show leaky BBB, but this permeability has been associated with improved clinical recovery. In the chronic stage (>6 weeks), an increase of BBB restoration factors leads the barrier to start decreasing its permeability. Nonetheless, permeability will persist to some degree several weeks after injury. Understanding the mechanisms behind BBB dysregulation and HT pathophysiology could potentially help guide acute stroke care decisions and the development of new therapeutic targets; however, effective translation into clinical practice is still lacking. In this review, we will address the different pathological and physiological repair mechanisms involved in BBB permeability through the different stages of ischemic stroke and their role in the development of HT and stroke recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Specifically, poly(lactide- co -glycolic) acid nanoparticles containing doxorubicin, cisplatin, and boldine resulted in an efficient internalization into the glioma cells, inducing cytotoxic effects [86] and an effective target-specific delivery [87]. Other polymeric nanocarriers for the treatment of brain cancer include polyethylene glycol and poly(ω-pentadecalactone- co - p -dioxanone) [88] or polyethylene glycol and poly(lactic- co -glycolic) acid [89] block copolymer nanoparticles which led to an improved drug release efficiency and a decrease in tumor size. Moreover, the administration of amphiphilic polymer-lipid nanoparticles containing docetaxel led to the in vivo accumulation at the tumor site, with an enhanced tumor growth inhibition and increased median survival compared to the equivalent clinical dose of docetaxel solution [90].…”

Section: Nanomedicine In Central Nervous System Disordersmentioning

confidence: 99%

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood–brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.

show abstract

“…The results showed a considerably higher translocation across the blood brain barrier, both for in vitro brain tumor models [40] and for numerical simulations using a three-dimensional brain tumor model reconstructed from magnetic resonance images [41]. Moreover, poly(lactic-co-glycolic acid) nanoparticles [42], block copolymer nanoparticles consisting of polyethylene glycol and poly(ω-pentadecalactone-co-p-dioxanone) [43], or of polyethylene glycol and poly(lactic-co-glycolic acid) [44], and hybrid nanoparticles using poly(lactic-co-glycolic acid), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(carboxy-poly(ethylene glycol)), and charged 1,2-dioleoyl-3-trimethylammonium-propane [45] have been used for the delivery of various anti-cancer drugs, all showing improved targeting and drug release efficiency, with a decrease in brain tumor size.…”

Section: The Use Of Nanoparticles For the Diagnosis And Treatment mentioning

confidence: 99%

Impact of Nanoparticles on Brain Health: An Up to Date Overview

Teleanu

Chircov

Grumezescu

et al. 2018

JCM

161

View full text Add to dashboard Cite

Nanoparticles are zero-dimensional nanomaterials and, based on their nature, they can be categorized into organic, inorganic, and composites nanoparticles. Due to their unique physical and chemical properties, nanoparticles are extensively used in a variety of fields, including medicine, pharmaceutics, and food industry. Although they have the potential to improve the diagnosis and treatment of brain diseases, it is fundamentally important to develop standardized toxicological studies, which can prevent the induction of neurotoxic effects. The focus of this review is to emphasize both the beneficial and negative effects of nanoparticles on brain health.

show abstract

RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy

Cited by 57 publications

References 35 publications

Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery

Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery

Neuronanomedicine: An Up-to-Date Overview

Impact of Nanoparticles on Brain Health: An Up to Date Overview

Contact Info

Product

Resources

About